Skip to Main Content

Advertisement

Skip Nav Destination
photo of Elaine R. Mardis, PhD photo of Lillian L. Siu, MD

Editors-In-Chief


Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University

Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto

Editors-In-Chief

Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University
    
Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto

Editors' Corner

Spotlight on Breast Cancer at Cancer Research Communications and the SABCS

The 2021 San Antonio Breast Cancer Symposium (SABCS) took place December 7–10, 2021 and was attended by thousands of participants, both virtually and in person. The SABCS, which has occurred annually...(read more)

 

Journal Sections

Cancer Research Communications welcomes high-quality research spanning the full spectrum of cancer science and medicine. This open access journal expands the AACR journal portfolio, stimulates the exchange of new ideas and approaches, and provides a rapid publication pathway. The below sections reflect the breadth of this new journal’s scope.

Featured Articles

Molecular and Cellular Biology
Deepankar Chakroborty, Veera K. Ojala et al.
Despite the relatively high frequency of somatic ERBB4 mutations in various cancer types, only a few activating ERBB4 mutations have been characterized, primarily due to lack of mutational hotspots in the ERBB4 gene. Here, we utilized our previously published pipeline, an in vitro screen for activating mutations, to ...
Tumor Biology
Fabienne Tschanz, Sabine Bender et al.
The cellular response to ionizing radiation (IR) depends on tumor cell and microenvironmental factors. Here, we investigated the role of IR-induced ADAM17 matrix metalloproteinase activity for the intercellular communication between tumor cells and the tumor vasculature in non–small cell lung cancer (NSCLC) tumor models. ...
Immuno-oncology
Talar Tokatlian, Grace E. Asuelime et al.
Neoantigens are among the most intriguing potential immuno-oncology targets because, unlike many cancer targets that are expressed on normal tissues, they are by definition restricted to cancer cells. Medicines directed at common neoantigens such as mutant KRAS are especially interesting because they may offer the ...
Emerging Technologies and Data Science
Talar Tokatlian, Grace E. Asuelime et al.
Neoantigens are among the most intriguing potential immuno-oncology targets because, unlike many cancer targets that are expressed on normal tissues, they are by definition restricted to cancer cells. Medicines directed at common neoantigens such as mutant KRAS are especially interesting because they may offer the ...
Therapeutic Research and Development
Kyle A. Cottrell, Luisangely Soto-Torres et al.
The RNA editing enzyme ADAR is an attractive therapeutic target for multiple cancers. Through its deaminase activity, ADAR edits adenosine to inosine in double-stranded RNAs. Loss of ADAR in some cancer cell lines causes activation of the type I IFN pathway and the PKR translational repressor, leading to inhibition of ...
Precision Medicine and Biomarkers
Glenn J. Hanna, Alessandro Villa et al.
Oral leukoplakia is common and may, in some cases, progress to carcinoma. Proliferative leukoplakia is a progressive, often multifocal subtype with a high rate of malignant transformation compared with the more common localized leukoplakia. We hypothesized that the immune microenvironment and gene expression patterns ...
Close Modal

or Create an Account

Close Modal
Close Modal